Abstracts tagged "Outcome measures"

Abstract Number: 1892 • ACR Convergence 2025
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
siddharth Agrawal¹, Freya Shah¹, Ritu Tated², Radhe Shah³ and Mahir Modi⁴, ¹landmark medical center, cumberland, RI, ²New York Medical College, Vallaha, ³Beth Israel Deaconess Medical Center, Boston, ⁴GCS Medical College, hospital and Research Centre, Ahmedabad, India
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention…
Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Philip J. Mease¹, Laure Gossec², Atul Deodhar³, Xenofon Baraliakos⁴, Frank Behrens⁵, Joseph F Merola⁶, Lihi Eder⁷, Ana-Maria Orbai⁸, Andreas Ramming⁹, Iain McInnes¹⁰, Alexis Ogdie¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁶Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
Abstract Number: 0628 • ACR Convergence 2025
Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Panagiotis Garantziotis¹, Dionysis Nikolopoulos², Spyridon Katechis³, Alp Temiz⁴, Danae-Mona Nöthling¹, Christina Adamichou⁵, Prodromos Sidiropoulos⁶, Georg Schett⁷, Fanouriakis Antonis³, Dimitrios Boumpas⁸ and George Bertsias⁹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical School University of Crete, Heraklion, Greece, Heraklion, Germany, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ⁹Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece
Background/Purpose: Organ damage drives morbidity and mortality in systemic lupus erythematosus (SLE), yet no validated tools exist to predict early damage. We aimed to develop…
Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Hideto Kameda¹, Toshiya Takahashi², Naoki Soeda² and Yoshiya Tanaka³, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…
Abstract Number: 0289 • ACR Convergence 2025
Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Didem Saygin¹, Matthew Diller², Varsha Surampudi³, Mark Bodkin³, Payam Farhadi⁴, Adam Schiffenbauer⁵, Audrey Kessel³, Chris Mecoli⁶, Rohit Aggarwal⁷, Helene Alexanderson⁸, Michelle Best⁹, Olivier Benveniste¹⁰, Hector Chinoy¹¹, Brian Feldman¹², Linda Kobert¹³, Manuel Lubinus¹⁴, Liza McCann¹⁵, Chester V. Oddis¹⁶, Nicolino Ruperto¹⁷, Jens Schmidt¹⁸, Victoria Werth¹⁹, Christie Bartels²⁰, Hanna Kim²¹, Andrew Mammen²², Julie Paik²³, Ellen M. Werner¹³, Ingrid de Groot²⁴, Pedro Machado²⁵, Susan Kim²⁶, Tahseen Mozaffar²⁷, Adam M Huber²⁸, Angelo Ravelli²⁹, Richard Scheuermann² and Lisa Rider³⁰, ¹Rush University Medical Center, Chicago, IL, ²National Library of Medicine, National institutes of Health, Bethesda, MD, ³Social Scientific System Inc, a DLH holding company, Baltimore, MD, ⁴National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁵National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Cure JM Foundation, Lessburg, VA, ¹⁰Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Myositis Association, Columbia, MD, ¹⁴Myositis Support and Understanding, Lincoln, DE, ¹⁵Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ¹⁸Immanuel University Hospital Ruedersdorf, Brandenburg Medical School, Rudersdorf, Germany, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ²¹NIAMS, NIH, Bethesda, MD, ²²NIH, Bethesda, MD, ²³Johns Hopkins Rheumatology, Baltimore, MD, ²⁴The Myositis Association, Rotterdam, Netherlands, ²⁵University College London, London, United Kingdom, ²⁶UCSF Benioff Children's Hospital, San Francisco, CA, ²⁷University of California, Irvine, Orange, CA, ²⁸IWK Grace Health Centre, Halifax, NS, Canada, ²⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ³⁰National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Recent progress has been made in developing myositis outcome assessments, response and classification criteria, and consensus in the design and conduct of clinical trials…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 2372 • ACR Convergence 2025
Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
Dana Rosenberg¹, Dafne capelusnik², Shai Shtrozberg³, Ori Elkayam⁴ and Reut Tzemach⁵, ¹Sourasky medical center Tel aviv ISRAEL, TEL AVIV, Israel, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Sourasky medical center Tel aviv ISRAEL, TEL AVIV, ⁴Tel Aviv medical center, Tel Aviv, Israel, ⁵Sourasky medical center Tel aviv ISRAEL, Tel Aviv-Yafo, Israel
Background/Purpose: In recent years, IL-23 inhibitors (IL23i)-have emerged as promising therapeutic options for psoriatic arthritis patients (PsA). Clinical trials have demonstrated their efficacy in both…
Abstract Number: 2210 • ACR Convergence 2025
Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
Dahima Cintron¹, Amanda Eudy², Michelle Petri³, Rebecca Fischer-Betz⁴, Abeer Mockbel⁵, Cecilia Nalli⁶, Laura Andreoli⁷, Angela Tincani⁸, Yair Molad⁹, Dafna D. Gladman¹⁰, Murray Urowitz¹¹, Stephen Balevic¹² and Megan Clowse¹³, ¹Duke Health, Durham, NC, ²Duke University, Raleigh, NC, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁵Cairo University/Kasr- AlAiny Medical School, Cairo, Egypt, ⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁷University of Brescia, Brescia, Brescia, Italy, ⁸ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ⁹Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Duke University, Durham, NC, ¹³Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE experience higher rates of adverse pregnancy outcomes. Among those with active SLE during pregnancy, lupus nephritis (LN) is associated with particularly…
Abstract Number: 1832 • ACR Convergence 2025
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Christine Lenchur¹, Niurka Liranzo Tejera¹, Adal Abonamah¹, Takemichi Matsui¹, Emily Cosentino¹, Priscilla Abate Namnum², Olga Marushchak¹, Melissa Akselrad¹, Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde³, Harleen Sidhu⁶, Emilia Bagiella⁵, Ian Wright⁵ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) face elevated risk of thrombotic events (TEs) due to traditional cardiovascular factors and chronic inflammation. Statins may offer…
Abstract Number: 1432 • ACR Convergence 2025
Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
Tae-Hwan Kim¹, Bora Nam², Jung Ho Yang³, So-Young Bang⁴, Ji Hui Shin⁵, Seunghun Lee⁶ and Tae-jong Kim⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Preventive Medicine, Graduate School of Chonnam National University, Gwangju, Republic of Korea, ⁴Hanyang University, Seoul, Republic of Korea, ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁶College of Medicine, Hanyang University, Seoul, Republic of Korea, ⁷Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea
Background/Purpose: This study evaluates the impact of the ASAS definition of early axial spondyloarthritis (axSpA) on radiographic progression over a 12-year period, utilizing the Modified…
Abstract Number: 1171 • ACR Convergence 2025
VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy
Marta López¹, Paula Garcia Escudero², Berta Magallares³, Meritxell Salles Lizarzaburu⁴, Dolly Viviana Fiallo Suárez⁵, Iñigo Rúa-Figueroa⁶, Isla Morante Bolado⁷, Elena Aurrecoechea⁸, Eugenia Enriquez⁹, Carolina Merino¹⁰, Santos Castañeda¹¹, Irene Monjo Henry¹², César Antonio Egües Dubuc¹³, Elena María Oliver García¹⁴, Alicia Garcia¹⁵, Judit Font-Urgelles¹⁶, Cristina Corrales¹⁷, Lourdes Villalobos¹⁸, Alina-Lucica Boteanu¹⁹, Ignacio Vázquez Gómez²⁰, Diego Dios²¹, Clara Garcia Belando²², Beatriz Frade Sosa²³, Delia Reina²⁴, Marta Ibañez²⁵, Irene Carrion²⁶, Maria Rodriguez²⁷, cristiana Sieiro²⁸, Francisco Javier Toyos²⁹, Alberto Mariano³⁰, Clara Moriano³¹, Rafael B. Melero-González³², Paloma Vela Casasempere³³, Jose Alberto Miranda³⁴, Giuliano Boselli³⁵, Jose Angel Hernandez³⁶, Ernesto Trallero³⁷, Elena Riera Alonso³⁸ and Jaime Calvo³⁹, ¹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ²H.U.Araba, Vitoria, ³Hospital de Sant Pau, Bareclona, ⁴Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ⁵H.U. Doctor Negrín, Gran Canarias, ⁶Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁷Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁸H. Sierrallana, Santander, ⁹Clínica Universidad de Navarra, Madrid, Spain, ¹⁰Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ¹⁴H.C. U. Lozano Blesa, Zaragoza, ¹⁵Rheumatologist, La Laguna, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹⁸Ramon y Cajal Hospital, MADRID, Spain, ¹⁹H.U. Ramón y Cajal, Madrid, Spain, ²⁰H.U. Doctor Peset, Valencia, ²¹H.U de A Coruña, A Coruña, Spain, ²²H.C. U. Virgen de la arrizaca, Murcia, ²³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁶Hospital del Mar, Barcelona, Spain, ²⁷H. Clínico San Carlos, Madrid, Spain, ²⁸Univrsity of Manchester, Manchester, United Kingdom, ²⁹Virgen Macarena University Hospital,, Sevilla, Spain, ³⁰Virgen del Rocío University Hospital, Sevilla, Spain, ³¹Hospital León, LEON, Castilla y Leon, Spain, ³²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ³³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³⁶Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ³⁷H. U. Vall d'Hebron, Barcelona, ³⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in UBA1 gene, characterized by systemic inflammation and haematologic abnormalities. Evidence regarding its…
Abstract Number: 0627 • ACR Convergence 2025
Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Omer Pamuk¹ and Ahmed Nasuhbeyoglu², ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Previous studies have shown a decline in systemic lupus erythematosus (SLE)-related mortality rates from 1999 to 2020. This study aimed to evaluate SLE-related mortality…
Abstract Number: 0316 • ACR Convergence 2025
Increased Synovial Inflammation, Xist Escape Gene Expression and Knee Pain in Females with Osteoarthritis
Bella Mehta¹, Miguel Otero², Michael Mazzucco³, Jenelys Ruiz-Ortega⁴, Caryn Hale⁴, Fuadur Omi⁴, Syed Henah Balkhi⁵, Purva Singh³, Samantha Lessard³, Wei Wang⁴, Maryam Aslam⁴, Tristan Maerz⁶, Peter Sculco³, Anne-Marie Malfait⁷, Xiaoshun Li⁸, Yiyuan Wu⁹, Shady Younis¹⁰, William Robinson¹¹, Daniel Ramirez¹², Edward DiCarlo¹² and Dana Orange⁵, ¹Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ²Hospital For Special Surgery, New York, ³Hospital For Special Surgery, New York, NY, ⁴The Rockefeller University, New York, ⁵The Rockefeller University, New York, NY, ⁶University of Michigan, Ann Arbor, MI, ⁷Rush University Medical Center, Chicago, ⁸Hospital For Special Surgery, Ridgewood, NY, ⁹Weill Cornell Medicine, New York, NY, ¹⁰Stanford University, Stanford, CA, ¹¹Stanford University, Palo Alto, CA, ¹²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: MRI evidence of synovitis and bone marrow lesions, but not cartilage degeneration associate with pain in osteoarthritis (OA). In this work, we integrated clinical,…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].